Infections caused by human alpha herpes viruses

Czech version

Authors: V. Boštíková ¹; M. Salavec ²; J. Smetana ¹; R. Sleha ¹; M. Coufalová ¹; M. Špliňo ¹; P. Boštík ^3,4
Authors‘ workplace: Katedra epidemiologie, FVZ UO, Hradec Králové ¹; Klinika nemocí kožních a pohlavních, FN a LF UK, Hradec Králové ²; Klinika infekčních nemocí, FN a LF UK, Hradec Králové ³; Centrum pokročilých studií, FVZ UO, Hradec Králové ⁴
Published in: Epidemiol. Mikrobiol. Imunol. 63, 2014, č. 3, s. 205-212
Category: Review articles, original papers, case report

Overview

Varicella-zoster virus (VZV), herpes simplex virus one (HSV-1) and herpes simplex virus two (HSV-2) represent three out of the eight known human herpesviruses and belong to the subfamily of α-herpesviruses. These viruses are present worldwide and humans are their sole host and reservoir. After the primary infection, these viruses persist in the body throughout life. The period of latency may be interrupted by reactivation of infection due to various factors. Each virus can induce a wide spectrum of diseases. The primary infection is typical for children and otherwise healthy individuals are often asymptomatic. It is mainly immunocompromised patients who are at risk of developing severe disease or complications when infected by these viruses. However, even in otherwise healthy individuals an infection by a-herpesviruses can run a severe course and lead to death.

Keywords:
Herpes Simplex Virus 1 and 2 – Varicella Zoster Virus

Sources

1. Norberg P. Diveregence and genotyping of human alpha herpesviruses: an overview. Infect Genet Evol, 2010;10:14–25.

2. Norberg P, et al. Diveregence and recombination of clinical herpes simplex virus type 2 isolates. J Virol, 2007; 81:13158–13187.

3. Norberg P, et al Complete-genome phylogenetic approach to VZV evolution. J Virol, 2006;80:9569–9576.

4. Arvin AM Chickenpox. Contrib Microbiol, 1999;3:6–110.

5.Weller TH Varicella-herpes zoster virus. In: Viral Infections of Humans: Epidemiology and Control. Evans AS, Kaslow RA, eds. New York: Plenum Press. 1997:865–892.

6. Norberg P, et al. Genotyping of clinical HSV1 isolates by use of restriction enzymes. J Clin Microbiol, 2006;44:4511–4514.

7. Hlinomazová Z. Herpetické onemocnění oka. Referátový výběr dermatovenerologie, 2013;5:14–19.

8. Gilden D, et al. Neurological disease produced by varicella zoster virus reactivation without rash. Curr Top Microbiol Immunol, 2010;342:243–253.

9. Tremolada S, et al Viral infections of the fetus and newborn infant. Pediatr Med Chir, 2008, 30:177–179.

10. Balfour HH. Antiviral drugs. N Engl J Med, 1999;340:1255–1268.

11. Zamora MR DNA viruses. Semin Respir Crit Care Med, 2011;32:454–470.

12. Kinchington PR et al. Herpes simplex virus and varicella zoster virus, the house guests who never leave. Herpesviridae, 2012;3:5.

13. Vanderpluym C, et al. Empiric acyclovir for neonatal herpes simplex virus infection. J Matern Fetal Neonatal Med, 2012;25:1278–1282.

14. Takeuchi S, et al. Herpes simplex virus encephalitis complicated by intracerebral hematoma. Neurol India, 2011; 59:594–596.

15. Mahy BWJ. Virology. 2011; Topley and Wilsons, USA.

16. Paticheep S, et al. Viral infection of CNS in children. J Med Assoc Thai, 2011;7:24–31.

17. Straus SS, et al. Biology, natural history, treatment and prevention. Ann Int Med, 1988; 108:221–237.

18. Griffiths PD. Herpesviruses and AIDS. J IHMF, 1994;1:5–11 .

19. Dworkin RH, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol, 2000; 60:1524–1534.

20. Eckhardt K, et al. Treatment of chronic and neuropathic pain. Established amitriptyline and the new gabapentin. MMW. Fortschr Med, 2000;142:28–30 .

21. Davidson AJ, et al. The complete DNA sequenze of varicella-zoster virus. J Gen Virol, 2000;67:1759–1816.

22. Doerr HW, et al. Dermatotrope Herpesviren. Infektionsbiologie, Epidemiologie und Diagnostik, Chemotherapie, 1996;1:1–8 .

23. Gross G,. et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol, 2003;26:277–289.

24. Gross G Varicella-zoster Virus In: Plettenberg A, Meigel W. (Hrsg.) Dermatologische Infektiologie. Blackwell, 2003:110–123 .

25. Johnson RW, et al. Guidelindes for the management of shingles. Report of a working group of the British Society for the Study of Infection (BSSI). J Infection, 1995; 30:193–200.

26. La Russa P, et al. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis, 1996;174:320–323 .

27. Liesegang TJ. Varicella zoster viral disease. Mayo Clin Proc, 1999;74:983–998.

28. Lilie HM, et al. Varicella-Zoster Virus, Kapitel: Shingles. Contrib Microbiol, 1999;3:111–128.

29. Lilie HM, et al. The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster. Drugs Aging, 2003;20:561–570.

30. Lungu O, et al.Varicella-zoster virus, latency and reactivation. Contrib Microbiol, 1999; 3: 61–75.

31. Arvin A. Varicella vaccine/genesis, efficacy, and attenuation. Virology, 2001; 284:153–158.

32. Boštíková V, et al. Atypicky se manifestující zosterová infekce vyvolaná neobvyklým divokým kmenem VZV. Vakcinologie, 2010;4:144–149.

33. Rothbart H, et al. Incorporation of VZV vaccination in childhood immunization schedules. Harefuah, 2008;147:693–697.

34. Levin MJ, et al. Herpes zoster with skin lesions and meningitis caused by two different genotypes of the Oka varicella-zoster vaccine. J Infect Dis, 2008;198:1444–1447.

35. Boštíková V, et al.Využití sekvenační analýzy divokých kmenů viru planých neštovic se zameřením na epidemiologickou situaci v České republice. Vakcinologie, 2009;2:55–59.

36. Boštíková V, et al. Problematika postvakcinačních komplikací u očkování proti viru varicella-zoster – popis klinického případu. Vakcinologie, 2011;1:6–9.

37. Boštíková V, et al. Molecular epidemiology of VZV. EMI, 2010;1:21–24.

38. Luman ET, et al. Uptake of varicella vaccination among young children in the United States: a success story in eliminating racial and ethnic disparities. Pediatrics, 2006;4:999–1008.

39. Loparev VN, et al. Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol, 2007;81:12758–12765.

40. Crooks RJ, et al. Zoster-associated chronic pain. Scand J Infect, 1991;80:62–68.

41. Sauerbrei A. Virologische und serologische diagnostic des herpes zoster. In: PEG DVV, 2. Konsensus Konferenz zur Therapie und Diagnostik des HZ. 2002:64-78.

42. Drolet M, et al. A prospective study of the HZ severity of illness. Clin J Pain, 2010;26: 656–666.

43. Levin MJ, et al. Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. VZV specific immune response in elderly recipients of a herpes zoster vaccine. J Infect Dis, 2008;197:825–835.

44. Schmader KE, et al. The impact of acute HZ pain and discomfort on functional status and quality of life in older adults. Clin J Pain, 2007;23:490–496.

45. Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med, 2007;352:2271–2284.

46. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology, 1995;45:41– 46.

47. Whitley RJ, et al. Disseminated HZ in the immunocompromised host: a comparative trial of acyclovir. J Infect Dis, 1992;165:450–455.

48. Pasqualucci A, et al. Prevention of post-herpetic neuralgia:acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone. Acta Anaesthesiol. Scand, 2000;44: 910–918.

49. Pervez A, et al. Concomitant bilaterall herpes zoster opthalmicus. Lancet Infect Dis,2002;2:699.

50. Huff JC, et al. Efficacy of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol, 1993;1:93–96.

51. Whitley RJ. Approaches to the treatment of VZV infections. In: VZV, molecular biology, pathogenesis and clinical aspects. Contrib Microbiol,1999;3:158–172.

52. Dworkin RH, et al. Recommendations for the managment of herpes zoster. Clin Infect Dis, 2007; 44:1–26.